Emcure Pharma IPO Details
| IPO Size | 1952.03 |
| Price Range | ₹960 - ₹1008 |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| Employee Discount | ₹90 per share |
| Listing at | NSE and BSE |
| Minimum Quantity | 14 |
| Investment (cut-off price) | ₹14,112 |
| Pre IPO Promotor Holding | 98.90% |
| Post IPO Promotor Holding | -- |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Emcure Pharma IPO Timelines
03/07/2024
Start Date05/07/2024
End Date09/07/2024
Refund Initiation09/07/2024
Credit of Shares to Demat Ac10/07/2024
Listing DateEmcure Pharma IPO Lot Size
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 14 | ₹14,112 |
| Retail Maximum | 14 | 196 | ₹197,568 |
| S-HNI Minimum | 15 | 210 | ₹211,680 |
| B-HNI Minimum | 71 | 994 | ₹10,01,952 |
Emcure Pharma IPO Subscription Status
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 195.83 x | 48.32 x | 7.21 x | 8.81 x | 67.87 x |
IPO Performance on Listing Day
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹1325.05 | ₹1359.315 | ₹1385 | ₹1325.05 |
Emcure Pharma IPO Company Financials
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2022 | ₹5918.86 | ₹4946.31 | ₹702.56 |
| FY 2023 | ₹6031.72 | ₹5278.36 | ₹561.85 |
| FY 2024 | ₹6715.24 | ₹5978.08 | ₹527.58 |
About Company
Emcure Pharmaceuticals, based in India, is involved in the development, manufacturing, and global marketing of pharmaceutical products spanning various therapeutic areas. The company has a product portfolio consisting of orals, injectables, and biotherapeutics. Emcure’s products reach over 70 countries worldwide.
The company operates 13 manufacturing facilities throughout India, equipped to produce pharmaceutical and biopharmaceutical products. These facilities handle dosage forms, including oral solids, oral liquids, and injectables—both liposomal and lyophilised. They manufacture biotherapeutics and complex active pharmaceutical ingredients (APIs), such as chiral molecules, iron molecules, and cytotoxic products.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 1981 | Healthcare | Satish Ramanlal Mehta |
Know Before Investing
Emcure Pharma IPO Strengths
- The company is well-placed in the domestic Market.
- It has demonstrated the Capabilities of Building Brands.
- It also has a Large, Diversified and Fast-Growing Product Portfolio in International Markets.
- The company also has Strong R&D Capabilities and manufacturing facilities.
- Experienced Board and senior management team.
Emcure Pharma IPO Risks
- The company is subject to extensive government regulations in India and international markets.
- High working capital requirements.
- It has reported negative cash flows in the past.
- Limited therapeutic areas contribute to a more significant portion of the total revenue in India.
- Its international operations expose the company to complex management, legal, tax and economic risks.
- Faces forex fluctuations risks.
- Its EBITDA and PAT have decreased in the last few financial years.
Swot Analysis for Emcure Pharma IPO
Strengths
Diversified across therapies
Weaknesses
Foreign currency risk, Declining margins
Opportunities
New product launches
Threats
High competition from both domestic and global players
Contact Details of IXIGO
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: [email protected]
Website: https://linkintime.co.in/initial_offer/public-issues.html
Company Details
Emcure Pharmaceuticals Limited
Plot No. P-1 and P-2,
IT-BT Park, Phase II, M.I.D.C.,
Hinjawadi, Pune -411 057
Phone: +91 20 3507 0033
Email: [email protected]
Website: https://www.emcure.com/
IPO Registar Details
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: [email protected]
Website: https://linkintime.co.in/initial_offer/public-issues.html
FAQs
The key objectives of Emcure Pharmaceuticals IPO are:
- Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by our Company;
- General corporate purposes.
Kotak Mahindra Capital Company Ltd, Axis Capital Ltd, J.P. Morgan India Pvt. Ltd, Jefferies India Pvt. Ltd are the book-running lead managers for the Emcure Pharmaceuticals IPO.